Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Vaccination Reaction Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Clinic Giessen and Marburg - Campus Giessen

Giessen, Hesse, 35392, Germany

About this study

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

being diagnosed with COVID-19 when kidney biopsy was performed
history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines

Exclusion criteria

Patient refuses participation

Treatment and study plan

Primary outcomes

Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases

Time frame: Kidney biopsy obtained during COVID-19 disease and up to 3 months after SARS-CoV-2 vaccination

Sponsors and collaborators

Lead sponsor

University of Giessen

Other

Collaborators

Universitätsklinikum Hamburg-Eppendorf

Registry information

Official study title

Kidney Histopathological Features in Patients After COVID-19 and SARS-CoV-2 Vaccination

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2022
First posted: Sep 14, 2021
Registry last updated: May 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed